Últimas noticias sobre Jiuzi Hldgs (NASDAQ:JZXN) Bolsa

Jiuzi Hldgs

Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.

Jiuzi Holdings Inc

In the last three months, 9 analysts have published ratings on ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for ConocoPhillips, presenting an average target of $135.78, a high estimate of $165.00, and a low estimate of $114.00. This current average has decreased by 0.8% from the previous average price target of $136.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1739188851_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive ConocoPhillips is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$157.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$134.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$134.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$123.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ConocoPhillips. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ConocoPhillips compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ConocoPhillips's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ConocoPhillips's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ConocoPhillips analyst ratings.</a>
<h2>Delving into ConocoPhillips's Background</h2>
ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.
<h3>ConocoPhillips's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, ConocoPhillips faced challenges, resulting in a decline of approximately -8.48% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.79%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ConocoPhillips's ROE excels beyond industry benchmarks, reaching 4.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ConocoPhillips's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.14%, the company showcases efficient use of assets and strong financial health.
Debt Management: ConocoPhillips's debt-to-equity ratio is below the industry average. With a ratio of 0.37, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where ConocoPhillips Stands With Analysts

Across the recent three months, 7 analysts have shared their insights on Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $445.71, a high estimate of $475.00, and a low estimate of $405.00. This current average has increased by 2.5% from the previous average price target of $434.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1739188843_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Home Depot. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$475.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$405.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$455.00</td>
<td>$455.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$465.00</td>
<td>$459.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$430.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Elizabeth Suzuki</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$440.00</td>
<td>$435.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Home Depot. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Home Depot compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Home Depot's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Home Depot's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Home Depot analyst ratings.</a>
<h2>Unveiling the Story Behind Home Depot</h2>
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The additions of the Company Store brought textiles to the lineup, and the recent tie-up with SRS will help grow professional demand in roofing, pool and landscaping projects.
<h3>Home Depot's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Home Depot's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 6.65%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Home Depot's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.07% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Home Depot's ROE excels beyond industry benchmarks, reaching 71.49%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Home Depot's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.76%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 10.95, Home Depot faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Home Depot Through The Eyes Of 7 Analysts

In the preceding three months, 4 analysts have released ratings for Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Viasat, revealing an average target of $14.75, a high estimate of $19.00, and a low estimate of $9.00. This current average has decreased by 32.95% from the previous average price target of $22.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1739188837_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Viasat is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Noel Parks</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mathieu Robilliard</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Viasat. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viasat compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Viasat's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Viasat's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VSAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Viasat analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Viasat's Background</h2>
Viasat Inc provides bandwidth technologies and services in three segments: satellite services: which provides satellite-based high-speed broadband services to consumers, enterprises, and commercial airlines; commercial networks: which develops end-to-end communication and connectivity systems; and government systems: which produces network-centric Internet Protocol-based secure government communication systems. A large majority of the firm's revenue is generated in the United States, it also has its presence in non U.S. countries.
<h3>Viasat: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Viasat's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -8.42%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Viasat's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -12.26%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.76%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Viasat's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.81%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Viasat's debt-to-equity ratio surpasses industry norms, standing at 1.88. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VSAT

Breaking Down Viasat: 4 Analysts Share Their Views

4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average target of $30.33, a high estimate of $46.00, and a low estimate of $6.00. Highlighting a 20.44% decrease, the current average has fallen from the previous average price target of $38.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1739188829_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of 4D Molecular Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Caufield</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Mani Foroohar</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Matthew Caufield</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Underweight</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Matthew Caufield</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 4D Molecular Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of 4D Molecular Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of 4D Molecular Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FDMT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on 4D Molecular Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About 4D Molecular Therapeutics</h2>
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
<h3>Financial Milestones: 4D Molecular Therapeutics's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: 4D Molecular Therapeutics's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -99.99%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: 4D Molecular Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1461433.33%, the company may face hurdles in effective cost management.
Return on Equity (ROE): 4D Molecular Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.68% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): 4D Molecular Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -7.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: 4D Molecular Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FDMT

A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts

Analysts' ratings for Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.5, a high estimate of $163.00, and a low estimate of $135.00. A decline of 8.54% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1739188820_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Qualys by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$135.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Michael Walkley</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Qualys. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Qualys compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Qualys's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Qualys's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/QLYS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Qualys analyst ratings.</a>
<h2>Delving into Qualys's Background</h2>
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
<h3>Key Indicators: Qualys's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Qualys's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 8.36%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Qualys's net margin is impressive, surpassing industry averages. With a net margin of 30.03%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Qualys's ROE excels beyond industry benchmarks, reaching 10.53%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Qualys's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 5.18%, the company showcases efficient use of assets and strong financial health.
Debt Management: Qualys's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

QLYS

Beyond The Numbers: 4 Analysts Discuss Qualys Stock

In the latest quarter, 4 analysts provided ratings for Wesbanco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSBC#NASDAQ">WSBC</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Wesbanco and provided 12-month price targets. The average target is $43.0, accompanied by a high estimate of $45.00 and a low estimate of $39.00. Observing a 8.86% increase, the current average has risen from the previous average price target of $39.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1739188813_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Wesbanco by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Manuel Navas</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Russell Gunther</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Daniel Tamayo</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$44.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Wesbanco. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Wesbanco compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Wesbanco's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WSBC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Wesbanco analyst ratings.</a>
<h2>Get to Know Wesbanco Better</h2>
Wesbanco Inc is a bank holding company that offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. The company has two reportable segments: community banking and trust and investment services. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. Its market service area primarily includes the Rust Belt region of the United States. Commercial real estate accounts for nearly half of the bank's loan portfolio. The bank has historically grown through both organic growth and acquisitions. The bank's primary component of net revenue is net interest income.
<h3>Wesbanco: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Wesbanco showcased positive performance, achieving a revenue growth rate of 9.16% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 28.91%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Wesbanco's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.78%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Wesbanco's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.25%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Wesbanco's debt-to-equity ratio surpasses industry norms, standing at 0.56. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WSBC

Forecasting The Future: 4 Analyst Projections For Wesbanco

News

Bristol Myers Reports Topline Results for Breyanzi In Adult Patients With Relapsed or Refractory Marginal Zone Lymphoma; Trial Met Primary Endpoint Of Overall Response Rate And Key Secondary Endpoint Of Complete Response Rate

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times

JP Morgan analyst Christopher Horvers maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Overweight and raises the price target from $97 to $112.

Price Target

JP Morgan Maintains Overweight on Walmart, Raises Price Target to $112

JP Morgan analyst Christopher Horvers maintains Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Overweight and raises the price target from $450 to $475.

JP Morgan Maintains Overweight on Home Depot, Raises Price Target to $475

B of A Securities analyst Ross Gilardi maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Underperform and raises the price target from $95 to $110.

B of A Securities Maintains Underperform on Oshkosh, Raises Price Target to $110

Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) with a Buy and maintains $150 price target.

Reiteration

PRAX

Needham Reiterates Buy on Praxis Precision Medicine, Maintains $150 Price Target

PLYA

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

U.S. stock futures rose on Monday after Friday&#8217;s sharp fall as investors digested the tariff updates and earnings reports. All four benchmark indices were trading higher.
Investors will look out for inflation data slated to be released on Wednesday this week.
The week&#8217;s corporate earnings calendar features a mix of companies across various sectors. Consumer-focused giants like McDonald&#8217;s Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), and Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) are set to report their financial results, alongside drugmakers Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>).
In the tech world, investors will be watching for updates from Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) and Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), as well as platforms like Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) and Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>).
The 10-year Treasury yield stood at 4.49%, while the two-year yield was at 4.28%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 91.5% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.61%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.38%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.27%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.32%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) both experienced positive premarket trading on Monday. SPY rose 0.47% to $603.57, and QQQ advanced 0.68% to $526.46, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
All sectors of the S&amp;P 500 closed <a href="https://www.benzinga.com/25/02/43585561/dow-dips-over-400-points-following-tariffs-threat-investor-sentiment-declines-fear-greed-index-in-fear-zone">lower</a> on Friday, with communication services, consumer discretionary, and materials leading the losses. President Donald Trump announced that &#8216;reciprocal tariffs&#8217; would take effect next week, further escalating trade tensions.
Investor sentiment was impacted by a mixed January jobs report, heightened inflation expectations, and concerns over trade tariffs. The University of Michigan's consumer sentiment survey showed a sharp rise in inflation expectations, with the one-year outlook reaching 4.3%, its highest since November 2023.
Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) reported stronger-than-expected fourth-quarter earnings, but its first-quarter sales guidance fell short of market expectations, forecasting net sales between $151 billion and $155.5 billion, below the $158.5 billion estimate.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.36%</td>
<td>19,523.40</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.95%</td>
<td>6,025.99</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.99%</td>
<td>44,303.40</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.19%</td>
<td>2,279.71</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
After Friday's sharp decline, Ryan Detrick, chief market strategist at Carson Research, highlighted that Mondays and Fridays have been weak for stocks so far in 2025.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Monday and Friday have been quite bad for stocks so far in 2025. The other three days have been solid. <a href="https://t.co/KMO8EiTWCR">pic.twitter.com/KMO8EiTWCR</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1888605947322417213?ref_src=twsrc%5Etfw">February 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Peter Mallouk, CEO of CPI Wealth, stated that &#8216;Cash is NOT King,&#8217; referencing a graphic showing that the cost of holding cash has risen over 2,000% in the past 30 years.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Over one-year periods, the average cost of holding cash has been roughly 8%. But over 30-year periods, this grows to more than 2,000%. Cash is NOT King. <a href="https://t.co/0dXlfOkGCD">pic.twitter.com/0dXlfOkGCD</a>
&mdash; Peter Mallouk (@PeterMallouk) <a href="https://twitter.com/PeterMallouk/status/1887864895468617828?ref_src=twsrc%5Etfw">February 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to the data underscored by Adam Turnquist, the chief technical strategist for LPL Financial, bullish sentiment has been gradually declining after remaining above average for most of last year.
"Currently, only about one-third of investors express a bullish outlook on stocks over the next six months, down approximately 8% from the previous week," he said.
However, Turnquist added that while sentiment is clearly not a science and usually follows price, the current degree of bearish sentiment could be considered a contrarian signal, "suggesting that the recent dip in stocks may have reached its low point."
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on this week:
<ul>
<li>There is no data scheduled to be released on Monday</li>
</ul>
<ul>
<li>On Tuesday, January&#8217;s NFIB optimism index data will be released at 6:00 a.m., ET.</li>
</ul>
<ul>
<li>Cleveland Fed President Beth Hammack will speak at 8:50 a.m., ET.</li>
</ul>
<ul>
<li>Federal Reserve Chair Jerome Powell will begin his testimony to Congress at 10:00 a.m. ET.</li>
</ul>
<ul>
<li>San Francisco Fed President Mary C Daly will speak at 10:20 a.m., and New York Fed President John C Williams and Fed Governor Michelle Bowman will speak at 3:30 p.m., ET.</li>
</ul>
<ul>
<li>On Wednesday, core and headline consumer price index data for January will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Fed Chairman Jerome Powell&#8217;s testimony to Congress continues at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>Atlanta Fed President Raphael Bostic will speak at 2:00 p.m. and New York Fed President Williams will speak again at 3:30 p.m., ET.</li>
</ul>
<ul>
<li>January&#8217;s monthly U.S. federal budget data will be out by 2:00 p.m., ET.</li>
</ul>
<ul>
<li>Fed Governor Christopher Waller will be speaking at 5:05 p.m., ET.</li>
</ul>
<ul>
<li>On Thursday, initial jobless claims till Feb. 8 will be out at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>The headline and core producer price index data for January will be released at 8:30 a.m., ET as well.</li>
</ul>
<ul>
<li>On Friday, January&#8217;s import price index data and U.S. retail sales will be out by 8:30 a.m., ET.</li>
</ul>
<ul>
<li>January&#8217;s industrial production data and capacity utilization data will be released at 9:15 a.m., ET.</li>
</ul>
<ul>
<li>Business inventories data for December will be announced at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>Dallas Fed President Lorie Logan will speak at 3:00 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>McDonald&#8217;s Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) was up 0.09% in premarket on Monday ahead of its earnings, which will be released before the opening bell. Analysts expect it to report quarterly earnings of $2.84 per share on revenue of $6.44 billion.</li>
</ul>
<ul>
<li>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) fell 2.15% as Wall Street expects it to report quarterly earnings of 97 cents per share on revenue of $1.76 billion before the opening bell.</li>
</ul>
<ul>
<li>Rockwell Automation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) slipped 0.58% ahead of its earnings, which will be released before the opening bell. Analysts expect it to report quarterly earnings of $1.59 per share on revenue of $1.88 billion.</li>
</ul>
<ul>
<li>Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) rose 0.36% as Wall Street expects it to report quarterly earnings of $4.03 per share on revenue of $2.78 billion after the closing bell.</li>
</ul>
<ul>
<li>Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) was up 3.20% despite being under scrutiny for its weight loss drug advertisement during the Super Bowl. Two U.S. senators expressed concerns over misleading information as the ad omitted any safety or side effect information.</li>
</ul>
<ul>
<li>MGO Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) was up 64.55% as the SEC approved its proposed business combination with Heidmar Inc.</li>
</ul>
<ul>
<li>T-Mobile Us Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) was up 3.98% after its satellite-based mobile network in the U.S. went live which automatically connects phones in areas without cellular coverage.</li>
</ul>
<ul>
<li>BP Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) was up 6.04% after reports claiming that Paul Singer&#8216;s hedge fund Elliott Management has built a stake in the oil major.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.17% to hover around $71.83 per barrel.
The gold spot index rose 1.41% to $2,900.64 per ounce after hitting a fresh record high of $2,906.2 today.. The Dollar Index was up 0.15% at 108.201 level.
Asian markets were mixed on Monday. Australia's ASX 200, South Korea's Kospi, and India's S&amp;P BSE Sensex index fell. Whereas, China's CSI 300, Hong Kong's Hang Seng, and Japan's Nikkei 225 index advanced. European markets were mostly higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43586493/jpmorgan-bofa-equifax-honda-block-and-many-more-may-get-relief-after-cfpb-dissolution-as-director-vought-halts-activities-maryland-senator-says-will-ensure-the-body-continues-to-fight-for-consumers">JPMorgan, BofA, Equifax, And Others May Get Relief After CFPB Dissolution: Maryland Senator Says He Will Ensure It Continues To &#8216;Fight For Consumers&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Earnings

Government

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

ETFs

AMAT

AMZN

COIN

CSCO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HOOD

MGOL

MRNA

SHOP

TMUS

VRTX

US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst

JP Morgan analyst Arun Jayaram initiates coverage on Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) with a Overweight rating and announces Price Target of $32.

Initiation

FLOC

JP Morgan Initiates Coverage On Flowco Holdings with Overweight Rating, Announces Price Target of $32

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Buy and maintains $36 price target.

HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

Jefferies analyst Lloyd Byrne initiates coverage on Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) with a Buy rating and announces Price Target of $35.

Jefferies Initiates Coverage On Flowco Holdings with Buy Rating, Announces Price Target of $35

Guidance

Spirit AeroSystems Expects Future Free Cash Flow Usage For Q1, Q2 2025  To Be $650M - $700M

Needham analyst Joseph Stringer maintains Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) with a Buy and lowers the price target from $38 to $10.

PLRX

Needham Maintains Buy on Pliant Therapeutics, Lowers Price Target to $10

Needham analyst Ryan Koontz reiterates Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) with a Buy and maintains $19 price target.

Needham Reiterates Buy on Viasat, Maintains $19 Price Target

Jiuzi Holdings enters into non-binding LOI for Shenzhen Maigesong acquisition

LE and DOGZ among Consumer Discretionary movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!



Moving stocks this morning are strong early morning trading, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>HWH International (NASDAQ:<a href="https://investorplace.com/stock-quotes/hwh-stock-quote/">HWH</a>) stock is rocketing more than 85% with strong early morning trading.</li>



<li>Zhongchao (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) shares are soaring over 50% with heavy pre-market trading.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is surging more than 30% with increasing trading activity on Thursday morning.</li>



<li>Brooge Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/brog-stock-quote/">BROG</a>) shares are rising over 21% as it also experiences strong trading today.</li>



<li>A.k.a. Brands (NYSE:<a href="https://investorplace.com/stock-quotes/aka-stock-quote/">AKA</a>) stock is increasing 17% without any clear news this morning.</li>



<li>Orgenesis (NASDAQ:<a href="https://investorplace.com/stock-quotes/orgs-stock-quote/">ORGS</a>) shares are gaining more than 16% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318209149&amp;type=PDF&amp;symbol=ORGS&amp;cdn=778bdb482c018a07a4dec09546e61eb2&amp;companyName=Orgenesis+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-04-02">following recent insider buying</a>.</li>



<li>Candel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cadl-stock-quote/">CADL</a>) stock is climbing over 15% despite a lack of news on Thursday.</li>



<li>AngioDynamics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ango-stock-quote/">ANGO</a>) shares are jumping more than 15% after releasing its <a href="https://www.nasdaq.com/press-release/angiodynamics-reports-fiscal-year-2024-third-quarter-financial-results-updates-fiscal">fiscal Q3 2024 earnings report</a>.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) stock is getting an over 14% boost as it continues to rally on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318212492&amp;type=PDF&amp;symbol=ADXN&amp;cdn=b99f04f9c986cd5ad74a2038763835fe&amp;companyName=Addex+Therapeutics+Ltd&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-03">neurological company launch</a>.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are up more than 13% without any clear news to report.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Casa Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/casa-stock-quote/">CASA</a>) stock is plummeting over 31% after <a href="https://www.nasdaq.com/press-release/casa-systems-initiates-court-supervised-chapter-11-sale-process-for-businesses-2024">filing for bankruptcy</a>.</li>



<li>View (NASDAQ:<a href="https://investorplace.com/stock-quotes/view-stock-quote/">VIEW</a>) stock is diving more than 29% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318216587&amp;type=PDF&amp;symbol=VIEW&amp;cdn=229f694a9f04258b182e980a2525d125&amp;companyName=View+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-04">alongside a delisting notice</a>.</li>



<li>Globavend (NASDAQ:<a href="https://investorplace.com/stock-quotes/gvh-stock-quote/">GVH</a>) shares are tumbling over 27% on Thursday morning.</li>



<li>Flora Growth (NASDAQ:<a href="https://investorplace.com/stock-quotes/flgc-stock-quote/">FLGC</a>) stock is taking a more than 20% beating after <a href="https://finance.yahoo.com/news/flora-growth-corp-announces-launch-003700210.html">launching a share offering</a>.</li>



<li>Achilles Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/achl-stock-quote/">ACHL</a>) shares are sliding over 19% alongside its <a href="https://www.nasdaq.com/press-release/achilles-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and">Q4 2023 earnings report</a>.</li>



<li>XTI Aerospace (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtia-stock-quote/">XTIA</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/04/why-is-xti-aerospace-xtia-stock-up-89-today/">after rallying yesterday</a>.</li>



<li>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) shares are declining over 13% ahead of its <a href="https://www.nasdaq.com/press-release/reliance-global-group-schedules-fourth-quarter-2023-financial-results-and-business">Q4 conference call</a>.</li>



<li>Jiuzi (NASDAQ:<a href="https://investorplace.com/stock-quotes/jzxn-stock-quote/">JZXN</a>) stock is slipping more than 13% as it continues to fall <a href="https://www.nasdaq.com/press-release/jiuzi-holdings-enters-into-a-non-binding-loi-for-the-acquisition-of-shenzhen">on acquisition plans</a>.</li>



<li>Digital Health Acqsuitiion (NASDAQ:<a href="https://investorplace.com/stock-quotes/dhac-stock-quote/">DHAC</a>) shares are dipping over 13% without any apparent news.</li>



<li>Telesis Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/">TBIO</a>) stock closes out our pre-market stock movers down more than 11%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-april-4th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

EC, ABAT and BORR among pre-market losers

Jiuzi Holdings received Nasdaq notification letters

Jiuzi Holdings announces 1-for-13 reverse share split

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. has finalized an employment agreement with Huijie Gao, appointing him as Chief F...

Jiuzi Holdings Announces New CFO and Employment Terms

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. reports a substantial increase in total assets, from $11.39 million to $56.22 mi...

Jiuzi Holdings Reports Surge in Total Assets

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. has entered into a share purchase agreement to sell all of its 100% equity inter...

Jiuzi Holdings Announces Major Equity Sale

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings Inc. has entered into a Securities Purchase Agreement to sell 500,000 ordinary shares ...

Jiuzi Holdings Sells Shares to International Investors

ABAT

ABIO

ACHL

ADXN

ANGO

AUVI

BORR

BROG

CADL

CASA

DHAC

DOGZ

DXYZ

EGOX

FLGC

GCTS

HSDT

HUBC

JZXN

KYCH

LGVC

LIFW

MAMO

ONMD

ORGS

RELI

REPX

TBIO

ULTA

VIEW

XTIA

ZCMD

Press Releases

Jiuzi Holdings Received Nasdaq Notification Letter Related to Late Filing of Annual Report on Form 20-F

Contracts

Jiuzi Holdings Enters into a Non-Binding LOI for the Acquisition of Shenzhen Maigesong

Jiuzi Holdings Received Nasdaq Notification Letters

Jiuzi Holdings Inc. Announces 1-For-13 Reverse Share Split

Jiuzi Holdings and Shenzhen Maigesong Terminate Negotiations to Focus on Future Growth

ARKO

Autozi Internet Technology (Global) Ltd. - Class A Ordinary Shares

Autozi Internet Tech

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Comments

Jiuzi Hldgs

Noticias

Últimas noticias sobre Jiuzi Hldgs (NASDAQ:JZXN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL